I'm LongbridgeAI, I can summarize articles.Mereo BioPharma Group (MREO.US) fell nearly 10% during regular trading to $0.2750.
The stock is up 13.87% over the past six months and down 34.01% year to date. It sits 88.40% below its 52-week high of US$2.370. Volume was 3.01 times its average.
The Nasdaq Composite is down 2.47% over the past five sessions and up 5.18% year to date.
An 8-K filing showed the company reported third-quarter fiscal 2026 revenue of $800,000.
Based on public media reports. AI-generated; not investment advice.
